The demographics of this cohort are presented in Table 1. The mean age at diagnosis was 53 years in the HSR group and 58 in the non-HSR group (P = .02). All 58 patients, including 36 ovarian cancers ...
Outcome of Induction and Postremission Therapy in Younger Adults With Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study Ninety patients were randomly assigned. Toxicity ...
Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer Patients with early breast cancer who had ...
Dec. 4, 2003 (San Antonio) — Docetaxel (Taxotere) produced better overall survival and longer time to progression than paclitaxel (Taxol) in a randomized head-to-head trial of the two taxanes widely ...
The company's docetaxel injection is the first nonalcohol formulation approved in the U.S., according to Teikoku. It also requires no prior dilution and is ready to add to the infusion solution. It is ...
Please provide your email address to receive an email when new articles are posted on . Men with metastatic castration-resistant prostate cancer had significantly longer OS with docetaxel rechallenge ...
BRIDGEWATER, NJ – June 5, 2004 – Aventis announced today the results of a phase III trial using Taxotere® (docetaxel) Injection Concentrate when added to a standard therapy for nonresectable locally ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — Docetaxel prolonged DFS and OS when added to radiation for cisplatin-ineligible patients with locally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results